NEW HAVEN, Conn., January 9, 2014 – Melinta Therapeutics today announced that Mary Szela, the Company’s chief executive officer, will be providing a corporate and clinical update at the 32nd annual J.P. Morgan Healthcare Conference in San Francisco, CA. Melinta’s presentation will take place on Wednesday, January 15, 2013 at 8:30am Pacific Time, and will include a clinical update on delafloxacin, the Company’s lead candidate for the treatment of acute bacterial skin and skin structure infections and uncomplicated gonorrhea. Delafloxacin is in Phase 3 clinical trials and has received Qualified Infectious Disease Product (QIDP) status for both indications.
The J.P. Morgan Healthcare Conference is the largest healthcare investment symposium in the industry, bringing together global industry leaders, emerging companies, technology innovators and members of the investment community. Attendance at this conference is by invitation only.
About Melinta Therapeutics
Melinta Therapeutics, based on the application of Nobel Prize-winning science, is dedicated to the discovery, development and commercialization of groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI) and uncomplicated gonorrhea. A key initiative at Melinta is to develop a new class of antibiotics designed to overcome the drug-resistant ESKAPE pathogens known to cause serious hospital infections. Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners. The company is headquartered in New Haven, CT with offices in Lincolnshire, IL.
For more information, visit www.melinta.com.